KALV - KalVista appoints Benjamin Palleiko as CEO
2024-03-07 06:51:28 ET
More on KalVista Pharmaceticals
- KalVista Is Still Cheap After Phase 3 Hereditary Angioedema Data
- KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
- KalVista: On Demand Oral Treatment For HAE Signifies Differentiated Advancement
- KalVista Pharmaceuticals up 16%, prices $160M offering